O	0	10	Randomized
O	11	16	trial
O	17	19	of
B-intervention	20	34	pentoxifylline
I-intervention	35	38	and
I-intervention	39	46	vitamin
I-intervention	47	48	E
O	49	51	vs
B-control	52	60	standard
I-control	61	67	follow
I-control	67	68	-
I-control	68	70	up
O	71	76	after
O	77	83	breast
O	84	95	irradiation
O	96	98	to
O	99	106	prevent
B-condition	107	113	breast
I-condition	114	122	fibrosis
O	122	123	,
O	124	133	evaluated
O	134	136	by
O	137	143	tissue
O	144	154	compliance
O	155	160	meter
O	160	161	.

O	162	164	To
O	165	172	conduct
O	173	174	a
O	175	185	randomized
O	186	194	clinical
O	195	200	trial
O	201	203	to
O	204	213	determine
O	214	221	whether
O	222	225	the
O	226	237	combination
O	238	240	of
O	241	255	pentoxifylline
O	256	257	(
O	257	260	PTX
O	260	261	)
O	262	265	and
O	266	273	vitamin
O	274	275	E
O	276	281	given
O	282	285	for
O	286	287	6
O	288	294	months
O	295	300	after
O	301	307	breast
O	307	308	/
O	308	313	chest
O	314	318	wall
O	319	330	irradiation
O	331	342	effectively
O	343	351	prevents
O	352	361	radiation
O	361	362	-
O	362	369	induced
O	370	378	fibrosis
O	379	380	(
O	380	383	RIF
O	383	384	)
O	384	385	.

B-total-participants	386	391	Fifty
I-total-participants	391	392	-
I-total-participants	392	397	three
B-eligibility	398	404	breast
I-eligibility	405	411	cancer
I-eligibility	412	420	patients
I-eligibility	421	425	with
I-eligibility	426	435	localized
I-eligibility	436	443	disease
O	444	448	were
O	449	457	enrolled
O	458	461	and
O	462	472	randomized
O	473	475	to
O	476	485	treatment
O	486	490	with
O	491	495	oral
O	496	499	PTX
O	500	503	400
O	504	506	mg
O	507	508	3
O	509	514	times
O	515	520	daily
O	521	524	and
O	525	529	oral
O	530	537	vitamin
O	538	539	E
O	540	543	400
O	544	546	IU
O	547	552	daily
O	553	556	for
O	557	558	6
O	559	565	months
O	566	571	after
O	572	581	radiation
O	582	583	(
O	583	584	n
O	584	585	=
B-intervention-participants	585	587	26
O	587	588	)
O	588	589	,
O	590	592	or
O	593	601	standard
O	602	608	follow
O	609	611	up
O	612	613	(
O	613	614	n
O	614	615	=
B-control-participants	615	617	27
O	617	618	)
O	618	619	.

O	620	626	Tissue
O	627	637	compliance
O	638	643	meter
O	644	645	(
O	645	648	TCM
O	648	649	)
O	650	662	measurements
O	663	667	were
O	668	676	obtained
O	677	679	at
O	680	682	18
O	683	689	months
O	690	692	to
O	693	700	compare
O	701	707	tissue
O	708	718	compliance
O	719	721	in
O	722	725	the
O	726	736	irradiated
O	737	740	and
O	741	750	untreated
O	751	757	breast
O	757	758	/
O	758	763	chest
O	764	768	wall
O	769	771	in
O	772	779	treated
O	780	788	subjects
O	789	792	and
O	793	801	controls
O	801	802	.

O	803	815	Measurements
O	816	820	were
O	821	829	obtained
O	830	832	at
O	833	834	2
O	835	841	mirror
O	842	847	image
O	848	853	sites
O	854	856	on
O	857	861	each
O	862	868	breast
O	868	869	/
O	869	874	chest
O	875	879	wall
O	879	880	,
O	881	884	and
O	885	888	the
O	889	896	average
O	897	907	difference
O	908	910	in
O	911	917	tissue
O	918	928	compliance
O	929	932	was
O	933	939	scored
O	939	940	.

O	941	952	Differences
O	953	955	in
O	956	959	TCM
O	960	972	measurements
O	973	977	were
O	978	986	compared
O	987	992	using
O	993	994	a
O	995	996	t
O	997	1001	test
O	1001	1002	.

O	1003	1011	Subjects
O	1012	1016	were
O	1017	1025	followed
O	1026	1027	a
O	1028	1035	minimum
O	1036	1038	of
O	1039	1040	2
O	1041	1046	years
O	1047	1050	for
O	1051	1056	local
O	1057	1067	recurrence
O	1067	1068	,
O	1069	1076	disease
O	1076	1077	-
O	1077	1081	free
O	1082	1090	survival
O	1090	1091	,
O	1092	1095	and
O	1096	1103	overall
O	1104	1112	survival
O	1112	1113	.

O	1114	1117	The
O	1118	1122	mean
O	1123	1133	difference
O	1134	1136	in
B-outcome	1137	1140	TCM
I-outcome	1141	1153	measurements
O	1154	1156	in
O	1157	1160	the
O	1161	1162	2
O	1163	1169	groups
O	1170	1173	was
O	1174	1175	0
O	1175	1176	.
O	1176	1178	88
O	1179	1181	mm
O	1181	1182	,
O	1183	1189	median
O	1190	1192	of
B-iv-cont-median	1193	1194	1
I-iv-cont-median	1194	1195	.
I-iv-cont-median	1195	1197	00
I-iv-cont-median	1198	1200	mm
O	1201	1202	(
O	1202	1209	treated
O	1209	1210	)
O	1211	1214	and
O	1215	1216	2
O	1216	1217	.
O	1217	1219	10
O	1220	1222	mm
O	1222	1223	,
O	1224	1230	median
O	1231	1233	of
B-cv-cont-median	1234	1235	2
I-cv-cont-median	1235	1236	.
I-cv-cont-median	1236	1237	4
I-cv-cont-median	1238	1240	mm
O	1241	1242	(
O	1242	1251	untreated
O	1251	1252	)
O	1252	1253	.

O	1254	1257	The
O	1258	1268	difference
O	1269	1276	between
O	1277	1280	the
O	1281	1282	2
O	1283	1289	groups
O	1290	1293	was
O	1294	1305	significant
O	1306	1307	(
O	1307	1308	P
O	1308	1309	=
O	1309	1310	.
O	1310	1314	0478
O	1314	1315	)
O	1315	1316	.

B-outcome	1317	1324	Overall
I-outcome	1325	1333	survival
O	1334	1335	(
B-iv-bin-percent	1335	1338	100
I-iv-bin-percent	1338	1339	%
O	1340	1347	treated
O	1347	1348	,
B-cv-bin-percent	1349	1351	90
I-cv-bin-percent	1351	1352	.
I-cv-bin-percent	1352	1353	6
I-cv-bin-percent	1353	1354	%
O	1355	1363	controls
O	1364	1366	at
O	1367	1368	5
O	1369	1374	years
O	1374	1375	)
O	1376	1379	and
B-outcome	1380	1387	disease
I-outcome	1387	1388	-
I-outcome	1388	1392	free
I-outcome	1393	1401	survival
O	1402	1403	(
B-iv-bin-percent	1403	1405	96
I-iv-bin-percent	1405	1406	.
I-iv-bin-percent	1406	1407	2
I-iv-bin-percent	1407	1408	%
O	1409	1416	treated
O	1416	1417	,
B-cv-bin-percent	1418	1420	86
I-cv-bin-percent	1420	1421	.
I-cv-bin-percent	1421	1422	8
I-cv-bin-percent	1422	1423	%
O	1424	1432	controls
O	1433	1435	at
O	1436	1437	5
O	1438	1443	years
O	1443	1444	)
O	1445	1449	were
O	1450	1453	not
O	1454	1467	significantly
O	1468	1477	different
O	1478	1480	in
O	1481	1484	the
O	1485	1486	2
O	1487	1493	groups
O	1493	1494	.

O	1495	1499	This
O	1500	1505	study
O	1506	1508	of
O	1509	1524	postirradiation
O	1525	1531	breast
O	1532	1538	cancer
O	1539	1547	patients
O	1548	1555	treated
O	1556	1560	with
O	1561	1564	PTX
O	1564	1565	/
O	1565	1572	vitamin
O	1573	1574	E
O	1575	1577	or
O	1578	1586	standard
O	1587	1593	follow
O	1593	1594	-
O	1594	1596	up
O	1597	1606	indicated
O	1607	1608	a
O	1609	1620	significant
O	1621	1631	difference
O	1632	1634	in
B-outcome	1635	1644	radiation
I-outcome	1644	1645	-
I-outcome	1645	1652	induced
I-outcome	1653	1661	fibrosis
O	1662	1664	as
O	1665	1673	measured
O	1674	1676	by
O	1677	1680	TCM
O	1680	1681	.

O	1682	1687	There
O	1688	1691	was
O	1692	1694	no
O	1695	1703	observed
O	1704	1710	impact
O	1711	1713	on
B-outcome	1714	1719	local
I-outcome	1720	1727	control
I-outcome	1728	1730	or
I-outcome	1731	1739	survival
O	1740	1746	within
O	1747	1750	the
O	1751	1756	first
O	1757	1758	2
O	1759	1764	years
O	1765	1767	of
O	1768	1774	follow
O	1774	1775	-
O	1775	1777	up
O	1777	1778	.

O	1779	1782	The
O	1783	1792	treatment
O	1793	1796	was
B-outcome	1797	1801	safe
O	1802	1805	and
B-outcome	1806	1810	well
I-outcome	1811	1820	tolerated
O	1820	1821	.

O	1822	1836	Pentoxifylline
O	1836	1837	/
O	1837	1844	vitamin
O	1845	1846	E
O	1847	1850	may
O	1851	1853	be
O	1854	1864	clinically
O	1865	1871	useful
O	1872	1874	in
O	1875	1885	preventing
O	1886	1894	fibrosis
O	1895	1900	after
O	1901	1910	radiation
O	1911	1913	in
O	1914	1918	high
O	1918	1919	-
O	1919	1923	risk
O	1924	1932	patients
O	1932	1933	.
